Malignant Solid Tumor

Oncology
10
Pipeline Programs
5
Companies
10
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
7
1
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 9 programs with unclassified modality

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
2 programs
1
1
ramucirumabPhase 2Monoclonal Antibody1 trial
LY2334737Phase 11 trial
Active Trials
NCT01648764Completed73Est. Nov 2012
NCT01515306Completed48Est. Feb 2021
Nektar Therapeutics
Nektar TherapeuticsSAN FRANCISCO, CA
1 program
1
NKTR-102 145 mg/m2Phase 21 trial
Active Trials
NCT01457118CompletedEst. Nov 2017
Bristol Myers Squibb
2 programs
1
1
BMS-986179Phase 1/21 trial
AVID200Phase 11 trial
Active Trials
NCT03834662Completed19Est. Feb 2020
NCT02754141Completed235Est. Oct 2021
EpicentRx
EpicentRxCA - La Jolla
4 programs
4
RRx-001Phase 11 trial
RRx-001Phase 11 trial
RRx-001Phase 11 trial
RRx-001Phase 11 trial
Active Trials
NCT02096341TerminatedEst. Jan 2016
NCT01359982CompletedEst. Feb 2015
NCT02801097TerminatedEst. Dec 2019
+1 more trials
Zai Lab
Zai LabCA - South SF
1 program
1
ZL-1218Phase 11 trial
Active Trials
NCT05859464Terminated34Est. Aug 2025

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Eli Lilly and Companyramucirumab
Nektar TherapeuticsNKTR-102 145 mg/m2
Bristol Myers SquibbBMS-986179
Zai LabZL-1218
Bristol Myers SquibbAVID200
EpicentRxRRx-001
EpicentRxRRx-001
EpicentRxRRx-001
EpicentRxRRx-001
Eli Lilly and CompanyLY2334737

Clinical Trials (10)

Total enrollment: 409 patients across 10 trials

NCT01515306Eli Lilly and Companyramucirumab

A Study of Ramucirumab (IMC-1121B) and Paclitaxel in Participants With Solid Tumors

Start: Jul 2012Est. completion: Feb 202148 patients
Phase 2Completed
NCT01457118Nektar TherapeuticsNKTR-102 145 mg/m2

An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies

Start: Oct 2011Est. completion: Nov 2017
Phase 2Completed
NCT02754141Bristol Myers SquibbBMS-986179

An Investigational Immuno-therapy Study of Experimental Medication BMS-986179 Given Alone and in Combination With Nivolumab

Start: Jun 2016Est. completion: Oct 2021235 patients
Phase 1/2Completed
NCT05859464Zai LabZL-1218

A Phase 1 Study of ZL-1218 in Subjects With Advanced Solid Tumors

Start: Jul 2023Est. completion: Aug 202534 patients
Phase 1Terminated
NCT03834662Bristol Myers SquibbAVID200

A Trial of AVID200, a Transforming Growth Factor β (TGFβ) Inhibitor, in Patients Malignancies

Start: Jan 2019Est. completion: Feb 202019 patients
Phase 1Completed
NCT02801097EpicentRxRRx-001

RRx-001 in Combination With Irinotecan in Metastatic or Advanced Cancer (PAYLOAD)

Start: Aug 2016Est. completion: Dec 2019
Phase 1Terminated
NCT02518958EpicentRxRRx-001

A Phase I, Open-Label, Multiple Ascending Dose Study of RRx-001 and Nivolumab

Start: Jul 2015Est. completion: Sep 2016
Phase 1Completed
NCT02096341EpicentRxRRx-001

A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Start: Apr 2014Est. completion: Jan 2016
Phase 1Terminated
NCT01359982EpicentRxRRx-001

Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects

Start: Sep 2011Est. completion: Feb 2015
Phase 1Completed
NCT01648764Eli Lilly and CompanyLY2334737

A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread

Start: Sep 2008Est. completion: Nov 201273 patients
Phase 1Completed

Related Jobs in Oncology

Senior Research Associate, Immuno-Oncology

SystImmune
2h ago
$60K - $85K/yr

Research Associate I/II, Immuno-Oncology

SystImmune
2h ago

Office Administrator

SystImmune
2h ago
$60K - $80K/yr

Scientist/Sr Scientist

TwoStep Therapeutics
San Carlos
3h ago

Senior Medical Project Manager (m/f/d)

Mindpeak
Hamburg
3h ago

Working Student Active Sourcing Support (m/f/d)

Mindpeak
Hamburg
3h ago

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

5 companies competing in this space

Related Indications

Breast Cancer(530)Non-small Cell Lung Cancer(373)Prostate Cancer(371)Multiple Myeloma(244)Advanced Solid Tumors(221)Acute Myeloid Leukemia(204)Cancer(187)Neoplasms(173)Colorectal Cancer(166)Advanced Solid Tumor(165)